**Core tip:** Results obtained in this retrospective study show that minimally modified FOLFIRI has improvement dramatically the efficacy of the FOLFIRI3-aflibercept combination with high response rates and survivals in patients with previously treated metastatic colorectal cancer, whatever prior use of irinotecan. A prospective randomized trial is planned to compare FOLFIRI-aflibercept to FOLFIRI3-aflibercept.

INTRODUCTION
============

Standard second-line therapy in patients with previously treated metastatic colorectal cancer (mCRC) is doublet fluoropyrimidine-based chemotherapy with either irinotecan (FOLFIRI) or oxaliplatin (FOLFOX), depending on the regimen used in first-line, in association with antiangiogenic agents (*e.g*., bevacizumab, aflibercept, ramucirumab) or anti-EGFR agents in absence of *RAS* tumor gene mutation (*e.g*., cetuximab, panitumumab)\[[@B1]-[@B8]\].

The standard FOLFIRI regimen was optimized by splitting the dose of irinotecan on day 1 \[half dose before 5-fluorouracil (5-FU)\] and day 3 (half dose after 5-FU) in the so-called FOLFIRI3 regimen\[[@B9]\]. Drugs and doses are similar to FOLFIRI, except for suppression of the 5-FU bolus. The response rate was higher than that reported for FOLFIRI\[[@B9],[@B10]\]. Based on these results, FOLFIRI3 became the second-line regimen of choice in some centers. Adding bevacizumab to FOLFIRI3 has shown promising efficacy results in two prior retrospective trials \[response rate 22% and 35%, median progression-free survival (PFS) 7.0 and 6.2 mo, median overall survival (OS) 13.0 and 10.8 mo, respectively\]\[[@B11],[@B12]\]. The addition of aflibercept to FOLFIRI in patients with pretreated mCRC increased response rate from 11% to 20% and improved median PFS from 4.7 to 6.9 mo \[hazard ratio (HR) = 0.76\] and median OS from 12.1 to 13.5 mo (HR = 0.82)\[[@B4]\]. Aflibercept was approved by the Food and Drug Administration on August 3, 2012 and by the European Medicines Agency on February 1, 2013 in combination with FOLFIRI for the treatment of patients with mCRC resistant to an oxaliplatin-containing regimen\[[@B13]\]. Based on the VELOUR study results and non-randomized FOLFIRI3 studies, we retrospectively analyzed the safety and efficacy of the FOLFIRI3-aflibercept combination as second or later-line therapy in patients with mCRC.

MATERIALS AND METHODS
=====================

This study was a retrospective, multicenter cohort, conducted in four French institutions (Centre Georges François Leclerc, Franco-British Hospital, University Hospital Besançon, and Saint-Antoine University Hospital) from September 2014 to December 2016.The main objective of this study was to evaluate the efficacy and safety profile of the aflibercept-FOLFIRI3 combination.

Population
----------

All patients with previously treated mCRC and with FOLFIRI3-aflibercept administered from September 2014 to December 2016 were included. During the inclusion period, the decision to give FOLFIRI3-aflibercept to each patient or another treatment regimen was at physician's discretion. Prior use of bevacizumab was allowed, but prior exposure to aflibercept was not permitted. Patients were divided into two subgroups depending on the prior use of irinotecan and the number of previous treatment lines for metastatic disease: (1) "irinotecan-naive\" population including patients with no more than one prior line of treatment for metastatic disease; and (2) the "irinotecan pre-exposed" population including patients for whom the number of prior treatment lines for metastatic disease was not restricted.

Treatment administration
------------------------

Treatment cycles were given intravenously every 14 d, as follows: Aflibercept 4 mg/kg over 1-h infusion (day 1), folinic acid 400 mg/m² over 2-h infusion (day 1), irinotecan 90 mg/m² over 60-90 min infusion (day 1), followed by continuous 5-FU 2400 mg/m² as a 46-h infusion (days 1 to 3), then irinotecan 90 mg/m² over 60-90 min infusion (day 3; Figure [1](#F1){ref-type="fig"}). Treatment information (date of treatment, doses) was collected using CHIMIO^®^ 5.4 (Computer Engineering, Paris, France) or BPC (GCS Emosist, Région Franche-Comté, France) softwares.
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Endpoints
---------

Treatment efficacy was evaluated with tumor response, PFS, and OS. The objective response rate (ORR) was defined as the proportion of patients having either complete response (CR) or partial response (PR) according to RECIST version 1.1. The best ORR was defined as the best response recorded from the start of treatment until progressive disease (PD). Disease control rate (DCR) was the sum of ORR and stable disease (SD). PFS was defined as the time from the date of starting treatment to the date of progression or death (from any cause). OS was defined as the time from the date of starting treatment to the date of patient death (from any cause) or to the last date the patient was known to be alive. Toxicity was evaluated according to the United States National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03.

Statistical analysis
--------------------

Follow-up and survival were estimated using the reverse Kaplan-Meier method and the Kaplan-Meier method, respectively, and were described using median with 95% confidence interval (CI). Qualitative variables were described using percent and means and continuous variables using medians (minimum-maximum). The cut-off date for statistical analysis was June 15, 2017. The final analysis was performed on the irinotecan-naïve and irinotecan pre-exposed populations.

RESULTS
=======

A total of 74 patients were treated (Figure [2](#F2){ref-type="fig"}). Nine patients were excluded from the analysis due to: Prior use of aflibercept (*n* = 3), more than one prior line of treatment in irinotecan-naïve patients (*n* = 3), or inadequate liver function (pretreatment alkaline phosphatase level \> 7 × upper normal limit, *n* = 3). Thirty patients did not receive prior irinotecan (the irinotecan-naïve population) and 35 were previously exposed to irinotecan (the pre-exposed population).
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Overall, 25 (38.5%) patients had an Eastern Cooperative Oncology Group performance status 0. The mean age was 63.1 years (range: 31.9-82.1); 23 (35.4%) had a single metastatic site, 49 (75.4%) had *RAS* mutated tumors, and two (3.1%) had *BRAF* mutated tumors. Prior use of bevacizumab and anti-EGFR were reported in 47 (72.3%) and 6 (9.2%) patients, respectively.

In the irinotecan-naïve population, five patients did not receive first-line therapy for metastatic disease (*n* = 4, early relapse after FOLFOX adjuvant therapy or *n* = 1, radiochemotherapy). In irinotecan pre-exposed population, 20 (57.1%) patients received more than two prior lines of treatment. Various irinotecan regimens (FOLFIRINOX, *n* = 21; FOLFIRI, *n* = 10; FOLFIRI3, *n* = 4) were previously given. The portion of patients with increased level of lactate dehydrogenase in the irinotecan pre-exposed population was higher than in that with the irinotecan-naïve patients (56.0% *vs* 17.6%; *P* = 0.027; Table [1](#T1){ref-type="table"}).

###### 

Patient characteristics *n* (%)

  **Characteristics**                         **Irinotecan-naive cohort**   **Irinotecan-pre-exposed cohort**   ***P*-value**
  ------------------------------------------- ----------------------------- ----------------------------------- ---------------
  Age (yr)                                                                                                      0.793
  \< 70                                       21 (70.0)                     23 (65.7)                           
  ≥ 70                                        9 (30.0)                      12 (34.3)                           
  Sex                                                                                                           0.623
  Male                                        16 (53.3)                     21 (60.0)                           
  Female                                      14 (46.7)                     14 (40.0)                           
  ECOG PS                                                                                                       0.227
  0                                           14 (46.7)                     11 (31.4)                           
  1                                           13 (43.3)                     15 (42.9)                           
  2                                           3 (10.0)                      9 (25.7)                            
  Time to metastasis                                                                                            0.314
  Metachronous                                9 (30.0)                      15 (42.9)                           
  Synchronous                                 21 (70.0)                     20 (57.1)                           
  No. of metastatic sites                                                                                       0.118
  1                                           14 (46.7)                     9 (25.7)                            
  \> 1                                        16 (53.3)                     26 (74.3)                           
  No. of prior lines for metastatic disease                                                                     
  \-                                                                                                            
  0                                           5 (16.7)                      0 (0.0)                             
  1                                           25 (83.3)                     15 (42.9)                           
  \> 1                                        \-                            20 (57.1)                           
  Prior drug exposure                                                                                           0.699
  Oxaliplatin                                 29 (96.7)                     35 (100.0)                          
  Bevacizumab                                 18 (60.0)                     29 (82.9)                           
  Anti-EGFR                                   2 (6.7)                       4 (11.4)                            

**ECOG PS: Eastern Cooperative Oncology Group performance status**.

Treatment exposure
------------------

In the irinotecan-naïve population, chemotherapy drugs (irinotecan and 5-FU) were given at standard dose in 12 (40.0%) patients. A lower dose of irinotecan and 5-FU were given in 15 (50.0%) and 4 (13.3%) patients, respectively. The median number of cycles was 8 (range: 1-19), and the median treatment duration was 3.7 mo (95%CI: 2.4-5.7). Dose reductions during treatment were performed in 7 (23.3%), 13 (43.3%), and 6 (20.0%) patients for aflibercept, irinotecan, and 5-FU, respectively. Granulocyte colony-stimulating factor (G-CSF) was given as primary prophylaxis in 14 (46.7%) patients and as secondary prevention in 3 (10.0%) patients. Erythropoietin was used in 5 (17.9%) patients. At the time of analysis, the treatment was still ongoing in 2 patients. The main reasons for stopping therapy were the occurrence of a limiting adverse event in 14 (46.7%) patients (diarrhea, *n* = 8; bleeding, *n* = 1; bowel perforation, *n* = 1; asthenia, *n* = 1; other, *n* = 3) or progression in 11 (36.7%) patients.

In the irinotecan pre-exposed population, chemotherapy drugs (irinotecan and 5-FU) were given at standard dose in 22 (62.9%) patients. A lower dose of irinotecan and 5-FU were given in 10 (28.6%), and 6 (17.1%) patients, respectively. The median number of cycles was 6 (range: 1-20), and the median treatment duration was 3.5 mo (95%CI: 2.1-5.6). Dose reductions during treatment were performed in 5 (14.3%), 9 (25.7%), and 7 (20.0%) patients for aflibercept, irinotecan, and 5-FU, respectively. G-CSF was given as primary prophylaxis in 13 (37.1%) patients and as secondary prevention in 2 (5.7%) patients. Erythropoietin was used in 3 (8.6%) patients. At the time of analysis, the treatment was still ongoing in 5 patients. The main reasons for stopping therapy were disease progression in 22 (62.9%) patients and the occurrence of limiting adverse events in 3 (8.6%) patients (diarrhea, *n* = 2; skin reactions, *n* = 1).

Response rate
-------------

In the irinotecan-naïve population, 4 (13.3%) patients were not evaluated for tumor response due to an early stop for limiting toxicity. ORR was reported in 13 patients \[43.3%, intention-to-treat (ITT); 50.0%, evaluable patients\] without CR, and DCR was reported in 23 patients (76.7%, ITT; 88.5%, evaluable patients). Three (10.0%) patients had PD at the first tumor evaluation (Table [2](#T2){ref-type="table"}).

###### 

Summary of the efficacy results

                  **Irinotecan-naïve, *n* = 30**   **Prior irinotecan, *n* = 35**                                          
  --------------- -------------------------------- -------------------------------- ------------- ------------ ----------- ------
  Response rate                                                                                                            
                  *n*                              \%                               \%            *n*          \%          \%
  (ITT)           (evaluable)                      (ITT)                            (evaluable)                            
  CR              0                                0                                0             1            2.8         2.9
  PR              13                               43.3                             50            11           31.4        32.4
  SD              10                               33.3                             38.5          9            25.7        26.5
  PD              3                                10                               11.5          13           37.1        38.2
  NE              4                                13.3                             \-            1            2.8         \-
  ORR             13                               43.3                             50            12           34.3        35.3
  DCR             23                               76.7                             88.5          21           60          61.8
  Survivals                                                                                                                
                  median, mo                       95%CI                                          median, mo   95%CI       
  PFS             11.3                             6.1-29.0                                       5.7          3.9-10.4    
  OS              17.0                             13.0-17.3                                      14.3         12.8-19.5   

**RR: Response rate; ITT: Intention-to-treat; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; NE: Not evaluable; ORR: Objective response rate; DCR: Disease control rate; PFS: Progression-free survival; OS: Overall survival**.

In the irinotecan pre-exposed population, one patient was not evaluable for tumor response (switch to intra-arterial chemotherapy after 2 treatment cycles). ORR was reported in 12 patients (34.3%, ITT; 35.3%, evaluable patients) including one CR, and DCR was reported in 21 patients (60.0%, ITT; 61.8%, evaluable population). Thirteen (37.1%) patients had PD at the first tumor evaluation (Table [2](#T2){ref-type="table"}). Among seven patients refractory to irinotecan, 1 (2.9%) had PR with FOLFIRI3-aflibercept, 2 (5.7%) had stable disease, 3 (8.6%) had PD, and 1 (2.6%) was not evaluable (Table [3](#T3){ref-type="table"}).

###### 

Contingency table of tumor response with FOLFIRI3-aflibercept according to prior tumor response with irinotecan \[*n* = 35, *n* (%)\]

                                               **FOLFIRI3-aflibercept**                                     
  -------------------------------- ----------- -------------------------- ----------- --------- ----------- -----------
  Prior irinotecan-based regimen   CR/PR       5                          3           7         0           15 (42.8)
  SD                               4           4                          2           0         10 (28.6)   
  PD                               1           2                          3           1         7 (20.0)    
  NE                               2           0                          1           0         3 (8.6)     
  All                              12 (34.3)   9 (25.7)                   13 (37.1)   1 (2.8)   35          

**CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; NE: Not evaluable**.

Survival
--------

The median follow-up was 13.6 mo (95%CI: 9.6-17.7) in the irinotecan-naïve population and 14.2 mo (95%CI: 11.0-21.5) in the pre-exposed population (*P* = 0.692). In the irinotecan-naïve population, median PFS was 11.3 mo (95%CI: 6.1-29.0) and median OS was 17.0 mo (95%CI: 13.0-17.3; Figure [3A](#F3){ref-type="fig"}). A lower starting dose of irinotecan (\< 90 mg/m²) did not impact PFS (*P* = 0.518) and OS (*P* = 0.311), but decreased the incidence of severe neutropenia (0.0% *vs* 30.8%, respectively, *P* = 0.041). In the irinotecan pre-exposed population, median PFS was 5.7 mo (95%CI: 3.9-10.4) and median OS was 14.3 mo (95%CI: 12.8 -19.5; Figure [3B](#F3){ref-type="fig"}).

![Progression-free survival and overall survival according to prior exposure to irinotecan (*n* = 65). A: Progression-free survival; B: Overall survival.](WJCO-9-110-g003){#F3}

Safety
------

In the irinotecan-naïve cohort, 17 (56.7%) patients experienced grade ≥ 3 toxicity (Table [4](#T4){ref-type="table"}). The most common (≥ 5%) grade 3-4 adverse events were diarrhea (*n* = 11, 36.7%), neutropenia (*n* = 4, 13.3%), anemia and mucositis (*n* = 3, 10.0%), and nausea and hypertension (*n* = 2, 6.7%). Any grade hemorrhage was reported in 4 (13.8%) patients, gastrointestinal perforation in 1 (3.3%) patient, and arterial thromboembolic event in 1 (3.3%) patient.

###### 

Selected (≥ 5%) grade 3-4 adverse events (NCI CTCAE version 4.0) *n* (%)

  **SOC**            **PT**             **Irinotecan-naïve**   **Prior irinotecan**   **All**
  ------------------ ------------------ ---------------------- ---------------------- -----------
  Any                                   17 (56.7)              15 (42.9)              32 (49.2)
  Blood              Neutropenia        4 (13.3)               1 (2.9)                5 (7.7)
                     Anemia             3 (10.0)               0 (0.0)                3 (4.6)
                     Thrombocytopenia   0 (0.0)                0 (0.0)                0 (0.0)
  Gastrointestinal   Nausea             2 (6.7)                0 (0.0)                2 (3.1)
                     Vomiting           1 (3.3)                0 (0.0)                1 (1.5)
                     Mucositis          3 (10.0)               3 (8.6)                6 (9.2)
                     Diarrhea           11 (36.7)              9 (25.7)               20 (30.8)
  Vascular           Hypertension       2 (6.7)                4 (11.4)               6 (9.2)

**SOC: System Organ Class; PT: Preferred term**.

In the irinotecan pre-exposed cohort, 15 (42.9%) patients experienced grade ≥ 3 toxicity (Table [4](#T4){ref-type="table"}). The most common (≥ 5%) grade 3-4 adverse events were diarrhea (*n* = 9, 25.7%), hypertension (*n* = 4, 11.4%), and mucositis (*n* = 3, 8.6%).

Salvage surgery
---------------

Salvage surgery for metastatic disease was performed in 7 (10.0%) patients (*n* = 4, liver; *n* = 1, lung; *n* = 1, liver and lung; *n* = 1, peritoneum). A complete (R0) resection and liver pathological complete response were observed in all and one patient, respectively.

DISCUSSION
==========

To our knowledge, this is the first report evaluating the FOLFIRI3-aflibercept combination in patients with previously treated mCRC. The response rate, which is a strong indicator of treatment efficacy, was unusually high not only in irinotecan-naïve patients (43%, ITT; 50%, evaluable), but also in irinotecan pre-exposed patients (34%, ITT, 35%, evaluable).

The median 11.3 mo PFS and median 17.0 mo OS in the irinotecan-naïve population receiving FOLFIRI3-aflibercept as second-line therapy compared favorably to the FOLFIRI-aflibercept combination in the pivotal phase III VELOUR study (response rate 19.8%, median 7.2 mo PFS, median 13.2 mo OS) and the FOLFIRI3 regimen without targeted agent (response rate 17%-23%, median 4-7 mo PFS, median 9-12 mo OS)\[[@B4],[@B9],[@B10],[@B14]\].

In the irinotecan pre-exposed population, patients received FOLFIRI3-aflibercept as salvage therapy. Yet, median PFS and OS were 5.7 mo and 14.3 mo, respectively, and were comparable to figures observed in second-line trials\[[@B8],[@B15]\].

A high portion (27%) of patients had to stop the FOLFIRI3-aflibercept combination because of limiting toxicity, mainly diarrhea. Its frequency (38%) was twice as common as in the VELOUR study (19%), but in the same range as in previous studies using FOLFIRI3. It has been demonstrated that severe diarrhea induced by aflibercept is due to microscopic colitis, which can be managed successfully using oral budesonide and/or mesalamine treatment\[[@B16],[@B17]\]. Placental growth factor (PlGF) could play a role in the occurrence of diarrhea. The absence of PlGF blocks dextransodium sulfate-induced colonic mucosal angiogenesis and increases mucosal hypoxia\[[@B18],[@B19]\]. Knockout of PlGF aggravates disease course in acute colitis\[[@B20]\]. Neutropenia and stomatitis were at a lower incidence than in the FOLFIRI-aflibercept arm of the pivotal VELOUR study (13.3% *vs* 36.7%, neutropenia; 10.0% *vs* 13.8%, stomatitis), which can be explained by deletion of the 5-FU bolus in the FOLFIRI3 regimen and use of G-CSF in 49% of patients. In the irinotecan-naïve population, a lower starting dose of irinotecan (\< 90 mg/m²) did not impact treatment efficacy, but decreased the incidence of severe neutropenia (0.0% *vs* 30.8%, *P* = 0.041).

The conversion to surgery of metastasis in second-line is another key finding that could modify the strategy in patients suitable for salvage surgery in case of response (sequential doublets versus triplets).The main limitation of this study is the retrospective design with a low number of patients. In conclusion, the combination of aflibercept and FOLFIRI3 in our study shows the encouraging efficacy results with high response rates and longer survivals in patients with previously treated mCRC, whatever the prior exposition to irinotecan. A randomized trial is warranted to compare FOLFIRI-aflibercept to FOLFIRI3-aflibercept.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

FOLFIRI3 is the second-line regimen of choice in patients with previously treated mCRC in some centers. Adding bevacizumab to FOLFIRI3 has shown promising efficacy results in two prior retrospective trials. The addition of aflibercept to FOLFIRI in patients with pretreated mCRC increased response rate from 11% to 20% and improved median PFS from 4.7 to 6.9 mo.

Research motivation
-------------------

The phase III VELOUR and non-randomized FOLFIRI3 studies results provide a backbone for our study.

Research objectives
-------------------

The main objective of the study is to evaluate the safety and efficacy of the FOLFIRI3-aflibercept combination as second or later-line therapy in patients with mCRC.

Research methods
----------------

Patients with previously treated mCRC were given the aflibercept-FOLFIRI3 combination and were divided into "irinotecan-naive" population including patients with no more than one prior line of treatment for metastatic disease, and the "irinotecan pre-exposed" population including patients for whom the number of prior treatment lines for metastatic disease was not restricted. The primary endpoint was overall response rate (ORR). Secondary endpoints were disease control rate, progression-free survival (PFS), overall survival (OS), and safety. Toxicity was evaluated according to the United States National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03.

Research results
----------------

Minimally modified FOLFIRI has improvement dramatically the efficacy of the FOLFIRI3-aflibercept combination with high response rates (43% in irinotecan-naïve patients and 34% in irinotecan pre-exposed patients) and survivals (median PFS: 11.3 mo, OS: 17.0 mo and PFS: 5.7 mo and OS: 14.3 mo, respectively) in patients with previously treated mCRC, whatever prior use of irinotecan.

Research conclusions
--------------------

The combination of aflibercept and FOLFIRI3 shows encouraging efficacy results in patients with previously treated mCRC.

Research perspectives
---------------------

A prospective randomized trial is planned to compare FOLFIRI-aflibercept to FOLFIRI3-aflibercept.
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